These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 34093744)

  • 41. Clinical efficacy of
    Basu S; Parghane RV; Naik C
    World J Nucl Med; 2020; 19(3):205-210. PubMed ID: 33354174
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors.
    McClellan K; Chen EY; Kardosh A; Lopez CD; Del Rivero J; Mallak N; Rocha FG; Koethe Y; Pommier R; Mittra E; Pegna GJ
    Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230691
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lu-177-Based Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors.
    Kim K; Kim SJ
    Nucl Med Mol Imaging; 2018 Jun; 52(3):208-215. PubMed ID: 29942399
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Initial clinical evaluation of indigenous
    Parghane RV; Mitra A; Bannore TU; Rakshit S; Banerjee S; Basu S
    World J Nucl Med; 2021; 20(1):73-81. PubMed ID: 33850492
    [No Abstract]   [Full Text] [Related]  

  • 45. Peptide receptor radionuclide therapy (PRRT) for GEP-NETs.
    Bergsma H; van Vliet EI; Teunissen JJ; Kam BL; de Herder WW; Peeters RP; Krenning EP; Kwekkeboom DJ
    Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):867-81. PubMed ID: 23582925
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life.
    Severi S; Grassi I; Nicolini S; Sansovini M; Bongiovanni A; Paganelli G
    Onco Targets Ther; 2017; 10():551-557. PubMed ID: 28203088
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeted
    Delpassand ES; Tworowska I; Esfandiari R; Torgue J; Hurt J; Shafie A; Núñez R
    J Nucl Med; 2022 Sep; 63(9):1326-1333. PubMed ID: 34992153
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prevalence of hitherto unknown brain meningioma detected on
    Parghane RV; Talole S; Basu S
    World J Nucl Med; 2019; 18(2):160-170. PubMed ID: 31040748
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gastroenteropancreatic Neuroendocrine Tumor Diagnosis: DOTATATE PET/CT.
    Kandathil A; Subramaniam RM
    PET Clin; 2023 Apr; 18(2):189-200. PubMed ID: 36585339
    [TBL] [Abstract][Full Text] [Related]  

  • 50. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).
    Zanini S; Renzi S; Giovinazzo F; Bermano G
    Front Endocrinol (Lausanne); 2020; 11():562505. PubMed ID: 33304317
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours.
    Severi S; Nanni O; Bodei L; Sansovini M; Ianniello A; Nicoletti S; Scarpi E; Matteucci F; Gilardi L; Paganelli G
    Eur J Nucl Med Mol Imaging; 2013 Jun; 40(6):881-8. PubMed ID: 23443937
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Radionuclide Therapy for Neuroendocrine Tumors.
    Cives M; Strosberg J
    Curr Oncol Rep; 2017 Feb; 19(2):9. PubMed ID: 28220446
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC.
    Severi S; Sansovini M; Ianniello A; Bodei L; Nicolini S; Ibrahim T; Di Iorio V; D'Errico V; Caroli P; Monti M; Paganelli G
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1955-63. PubMed ID: 26112388
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
    Kesavan M; Claringbold PG; Turner JH
    Neuroendocrinology; 2014; 99(2):108-17. PubMed ID: 24714208
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Peptide Receptor Radionuclide Therapy.
    Hofland J; Brabander T; Verburg FA; Feelders RA; de Herder WW
    J Clin Endocrinol Metab; 2022 Nov; 107(12):3199-3208. PubMed ID: 36198028
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Somatostatin receptor saturation after administration of high peptide amounts of [
    Siebinga H; Veerman CHAM; de Wit-van der Veen L; Stokkel MPM; Hendrikx JJMA; Aalbersberg EA
    EJNMMI Res; 2022 Dec; 12(1):74. PubMed ID: 36515683
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Induction of Anti-Tumor Immune Responses by Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE in a Murine Model of a Human Neuroendocrine Tumor.
    Wu Y; Pfeifer AK; Myschetzky R; Garbyal RS; Rasmussen P; Knigge U; Bzorek M; Kristensen MH; Kjaer A
    Diagnostics (Basel); 2013 Oct; 3(4):344-55. PubMed ID: 26824927
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials.
    Cives M; Soares HP; Strosberg J
    Curr Opin Oncol; 2016 Jul; 28(4):359-66. PubMed ID: 27138571
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Uri I; Grozinsky-Glasberg S
    Clin Diabetes Endocrinol; 2018; 4():16. PubMed ID: 30009041
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PLGA nanoparticles for peptide receptor radionuclide therapy of neuroendocrine tumors: a novel approach towards reduction of renal radiation dose.
    Arora G; Shukla J; Ghosh S; Maulik SK; Malhotra A; Bandopadhyaya G
    PLoS One; 2012; 7(3):e34019. PubMed ID: 22442740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.